

Lunch & Learn: ATMPs Uncovered – Fundamentals, Promises, and Real-World Challenges

Date:

25-Nov-2025 12.00 pm - 01.30 pm

Venue:

Online (Microsoft Teams)

Registration deadline:

24-Nov-2025

Costs:

Free of charge

Type:

Informationsveranstaltung

Target group:

Scientists and researchers, Medical professionals, Representatives from Biotech and Pharma industry, Students and young professionals, Clinical research and regulatory experts, Innovation managers

Organiser:

BIOPRO Baden-Württemberg GmbH BioRN Life Science Cluster (PRECISEU project partner)

Contact:

BIOPRO Baden-Württemberg GmbH Romy Wentenschuh

Email: wentenschuh(at)bio-pro.de Phone: +49 (0) 711 218185 79

Language: English

Links:

rack Register to the Lunch & Learn



Are you interested in the latest developments in the field of Advanced Therapy Medicinal Products (ATMPs)? If so, we warmly invite you to our Lunch & Learn event!

Experience the future of medicine at our online event: "ATMPs Uncovered – Fundamentals, Promises, and Real-World Challenges."

ATMPs represent innovative medicines that open up new avenues for treating serious and previously incurable diseases. They are divided into three key pillars:

- Gene Therapies: Therapeutic genes are specifically introduced into cells to correct genetic defects or combat diseases.
- Cell Therapies: Living cells are used as medicines to replace damaged tissue or to precisely modulate the immune system.
- Tissue Engineering: Artificially produced or modified tissues are used to regenerate or replace body structures.

Our event places particular emphasis on **virus-based therapies**. These involve the targeted use of viruses either as vectors for therapeutic genes or as oncolytic agents against tumour cells. These approaches are considered key to personalised medicine and enable individually tailored treatments with high efficacy and fewer side effects. Some virus-based therapies have an oncolytic effect, but by no means all of them are part of gene therapy.

The program will also cover current developments in **tissue engineering**. In this area, cells and biomaterials are used to create functional tissues for regenerative medicine and to open up new treatment possibilities.

Look forward to concise, practice-oriented presentations on all three ATMP pillars. Our experts will provide insights into current research, challenges in development and manufacturing, and future perspectives for these promising therapies.

Take advantage of this opportunity to expand your knowledge during your lunch break, network with others, and be inspired by innovative approaches.

This Lunch & Learn session is part of the **PRECISEU Personalised Medicine (PM) School**, an event dedicated to promoting knowledge and skills in personalised medicine. PRECISEU is a European project under Horizon Europe with 25 partners from 11 countries and Ukraine. Its goal is to connect innovation ecosystems, accelerate the adoption of personalised medicine, and establish advanced therapies across Europe.

The event will be recorded and subsequently published as a learning tool on the PRECISEU website.

Agenda of Lunch & Learn

12:00 - 12:10 pm:

Welcome and introduction

Romy Wentenschuh - Project manager (International, PRECISEU) | BIOPRO Baden-Württemberg GmbH

12:10 - 12:40 pm:

"ATMP Basics and Challenges in Implementation" and Q&A

- Dr. Friedemann Loos Innovation Manager | bioRN Life Science Cluster (Baden-Württemberg, Germany)
- Dr. Kristina Levan Business Developer | Business Region Göteborg (BRG)

12:40 - 01:10 pm:

"Solving challenges in virus-based therapies development through collaboration" and Q&A

- Dr.-Ing. Friederike Eilts Team lead of process technologies on virus-based therapies | Virus-Based Technologies (VBT) department at Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) (Baden-Württemberg, Germany)
- Dr. Till Wenger Head of Development Core Technologies | Virus Therapeutics Center at Boehringer Ingelheim Pharma GmbH & Co. KG (Baden-Württemberg, Germany)

01:10 - 01:35 pm

"Advancing Tissue Engineering into Tissue Therapeutics that can cure serious disease" and Q&A

• Dr. Petter Björquist - CEO | Verigraft (Gothenburg, Sweden)

01:35 - 01:45 pm:

Closing remarks

Source

BIOPRO Baden-Württemberg GmbH

More about PRECISEU:



As part of the PRECISEU Summer School:

Personalised Medicine school

Organisator:



Marketing-partner:



